---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069155"
form_type: "8-K"
ticker: "ENTA"
cik: "0001177648"
company_name: "ENANTA PHARMACEUTICALS INC"
filed_at: "2025-05-12T23:59:59+00:00"
generated_at: "2026-05-21T23:06:08.834620+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Enanta Q2 net loss narrows to $22.6M; RSV study enrollment target met

## Summary
- Revenue $14.9M, down 13% YoY from $17.1M; net loss $22.6M ($1.06 loss per share) vs $31.2M ($1.47) in prior year.
- Cash and marketables $193.4M at March 31; plus $33.8M tax refund in April; expects runway into fiscal 2028.
- Phase 2 RSVHR study of zelicapavir met enrollment target of 180 high-risk adults; topline data expected late Q3 2025.
- STAT6 program: plan to select development candidate in 2H 2025; KIT inhibitor EPS-1421 IND-enabling studies ongoing.
- Filed opening brief in patent infringement appeal against Pfizer over Paxlovid; original case filed June 2022.

## SEC filing metadata
- accession: 0000950170-25-069155
- form_type: 8-K
- ticker: ENTA
- cik: 0001177648
- company_name: ENANTA PHARMACEUTICALS INC
- filed_at: 2025-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1177648/000095017025069155/0000950170-25-069155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1177648/000095017025069155/enta-20250512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069155
- JSON: https://secwatch.observer/filing/0000950170-25-069155.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069155.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.